CLINICAL TRIALS PROFILE FOR TAGAMET HB 200
✉ Email this page to a colleague
All Clinical Trials for TAGAMET HB 200
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00038402 ↗ | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer | Completed | Genentech, Inc. | Phase 3 | 2001-04-01 | The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods. |
| NCT00038402 ↗ | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer | Completed | M.D. Anderson Cancer Center | Phase 3 | 2001-04-01 | The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods. |
| NCT00233935 ↗ | Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus | Completed | National Cancer Institute (NCI) | Phase 1 | 2005-11-01 | The goal of this clinical research study is to test the safety of defined green tea catechin extract at different dose levels. Researchers also want to find out what effects, good and bad, it may have on individual and their risk for esophagus cancer. Esophagus cancer is an increased risk associated with Barrett's esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of defined green tea catechin extract may prevent esophageal cancer. |
| NCT01256879 ↗ | Cimetidine Biowaivers | Completed | Food and Drug Administration (FDA) | Phase 4 | 2011-03-01 | The purpose of this research is to see if non-drug ingredients in capsules and oral solutions affect how well drugs are absorbed. This is called "bioequivalence." Medications taken by mouth, such as capsules and solutions, need to be absorbed into the body in order to do any good. Capsules and solutions contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the capsules and solutions can impact how much drug is absorbed into the body. This is called "bioINequivalence." Capsules and solutions in this research contain the drug cimetidine. This drug is being used since it has high water solubility (can dissolve in water) and low ability to be absorbed. |
| NCT01256879 ↗ | Cimetidine Biowaivers | Completed | University of Maryland | Phase 4 | 2011-03-01 | The purpose of this research is to see if non-drug ingredients in capsules and oral solutions affect how well drugs are absorbed. This is called "bioequivalence." Medications taken by mouth, such as capsules and solutions, need to be absorbed into the body in order to do any good. Capsules and solutions contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the capsules and solutions can impact how much drug is absorbed into the body. This is called "bioINequivalence." Capsules and solutions in this research contain the drug cimetidine. This drug is being used since it has high water solubility (can dissolve in water) and low ability to be absorbed. |
| NCT01256879 ↗ | Cimetidine Biowaivers | Completed | University of Maryland, Baltimore | Phase 4 | 2011-03-01 | The purpose of this research is to see if non-drug ingredients in capsules and oral solutions affect how well drugs are absorbed. This is called "bioequivalence." Medications taken by mouth, such as capsules and solutions, need to be absorbed into the body in order to do any good. Capsules and solutions contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the capsules and solutions can impact how much drug is absorbed into the body. This is called "bioINequivalence." Capsules and solutions in this research contain the drug cimetidine. This drug is being used since it has high water solubility (can dissolve in water) and low ability to be absorbed. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAGAMET HB 200
Condition Name
| Condition Name for TAGAMET HB 200 | |
| Intervention | Trials |
| Stress Ulcer Prophylaxis | 1 |
| Anatomic Stage IIIC Breast Cancer AJCC v8 | 1 |
| Prognostic Stage IA Breast Cancer AJCC v8 | 1 |
| Anatomic Stage 0 Breast Cancer AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for TAGAMET HB 200
Trials by Country
Clinical Trial Progress for TAGAMET HB 200
Clinical Trial Phase
Clinical Trial Sponsors for TAGAMET HB 200
Sponsor Name
| Sponsor Name for TAGAMET HB 200 | |
| Sponsor | Trials |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2 |
| National Cancer Institute (NCI) | 1 |
| Food and Drug Administration (FDA) | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
